Quince Therapeutics
QNCX
85 hedge funds and large institutions have $99.5M invested in Quince Therapeutics in 2022 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 21 increasing their positions, 31 reducing their positions, and 22 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.04% less ownership
Funds ownership: 0.32% → 0.28% (-0.04%)
11% less call options, than puts
Call options by funds: $4.92M | Put options by funds: $5.54M
12% less funds holding
Funds holding: 97 → 85 (-12)
32% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 31
55% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 22
59% less capital invested
Capital invested by funds: $241M → $99.5M (-$142M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$3.95M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$2.09M |
| 3 |
PP
PDT Partners
New York
|
+$1.91M |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
+$1.02M |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$710K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$18.4M |
| 2 |
Millennium Management
New York
|
-$3.4M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.41M |
| 4 |
Walleye Capital
New York
|
-$1.73M |
| 5 |
Morgan Stanley
New York
|
-$1.48M |
QNCX Hedge Fund Activity: Q1 2022 in Review
85 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Quince Therapeutics (QNCX) for Q1 2022, worth a combined $99.5M — down 59% from $241M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of QNCX and 10 opened new positions — a net loss of 12 holders — while 31 trimmed existing stakes and 21 added.
The largest buyer was JP Morgan Chase, adding an estimated $3.95M. The largest seller was Capital International Investors, exiting entirely with an estimated $18.4M sold.
- 85 institutional investors held Quince Therapeutics (QNCX) as of Q1 2022, down from 97 in Q4 2021.
- Funds reported $99.5M of Quince Therapeutics stock for Q1 2022, down 59% quarter-over-quarter.
- 10 funds opened new Quince Therapeutics positions in Q1 2022 and 22 closed out, a net change of -12 holders.
- The largest Quince Therapeutics buyer in Q1 2022 was JP Morgan Chase, an estimated $3.95M added.
- The largest Quince Therapeutics seller in Q1 2022 was Capital International Investors, an estimated $18.4M sold.
Based on aggregated 13F filings for Q1 2022.